Alpha-Lipoic Acid (ALA) IV Therapy

Alpha-lipoic acid (ALA) — uniquely both water- and fat-soluble — is the "universal antioxidant," a mitochondrial-origin molecule effective in compartments where most antioxidants cannot reach. Used clinically since the 1960s, ALA has become a cornerstone of longevity, neuropathy and metabolic-support protocols.

Mechanism

ALA serves as a cofactor for pyruvate dehydrogenase and α-ketoglutarate dehydrogenase complexes — directly involved in cellular energy production within mitochondria. As an antioxidant it neutralises free radicals and — uniquely — regenerates vitamin C, vitamin E, glutathione and CoQ10, strengthening the antioxidant network. This recycling role separates ALA from other antioxidants.

ALA is also a heavy-metal chelator (lead, mercury, arsenic), improves insulin signalling, suppresses NF-κB-driven inflammation and activates the Nrf2 antioxidant pathway. This multi-mechanism profile makes it useful in both acute and chronic disease support.

Clinical Indications

Diabetic neuropathy: ALA's strongest evidence-based indication. IV ALA (600 mg, 5 days/week for 3 weeks) — approved in Germany — significantly reduces burning, tingling and numbness in large RCTs (ALADIN, SYDNEY-2).

Metabolic syndrome and insulin resistance: ALA enhances glucose uptake by activating GLUT4 transporter — improving HbA1c and fasting glucose.

Liver health: hepatoprotective in NAFLD, chronic hepatitis adjunct and toxin-driven liver injury — paired with glutathione.

Neurological support: studied in glaucoma, early Alzheimer signs, peripheral neuropathy and chemotherapy-induced neuropathy for neuroprotective effects.

Skin and aesthetics: topical and systemic ALA boosts skin antioxidant capacity and reduces protein glycation (AGE formation), with anti-ageing effects on the skin.

IV Protocol and Combinations

Standard IV ALA: 300–600 mg per session in 100–250 mL saline, infused over 30–60 minutes. General longevity: 1–2 sessions/week for 6–10 sessions. Diabetic neuropathy: intensive phase (5 sessions/week × 3 weeks) followed by maintenance.

ALA combines synergistically with glutathione, vitamin C, B-complex and magnesium. Major ozone therapy combined with ALA targets mitochondria and antioxidant defence simultaneously.

Safety and Contraindications

Well tolerated. Rare side effects (nausea, dizziness, skin rash) during infusion. In patients with thiamine (B1) deficiency — especially after bariatric surgery or with alcohol-use disorder — thiamine loading is required before IV ALA to prevent Wernicke encephalopathy. Pregnancy data are limited; not routinely used. In patients on insulin or oral antidiabetics, glucose is closely monitored.